INCREASING INCIDENCE OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION

Authors

  • Ioana-Florina IORDAN “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Anca-Maria ADAVIDOAIEI “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Irina-Adriana SAVU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • E NASTASE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Florina FILIP-CIUBOTARU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Carmen MANCIUC “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Keywords:

RECURRENT CLOSTRIDIUM DIFFICILE INFECTION, VANCOMYCIN, COMORBIDITIES, MULTIDISCIPLINARY COLLABORATION

Abstract

Clostridium difficile infection continues to be a major cause of infectious enterocol-itis, commonly associated with antibiotic use. Infection can lead to relapses, reason why it is considered by clinicians a true challenge. Aim: To determine the incidence of recurrent Clos-tridium difficile infection in patients admitted to the Iasi Infectious Diseases Hospital over a six-month period. Material and methods: Of the 195 admitted patients, 46 presented for the recurrence of colitis. Data from medical records had been used to identify the patients who met the inclusion criteria. Results: Most of the 46 relapses were recorded in individuals aged over 60 with multiple associated comorbidities. The test for Clostridium difficile toxin was positive in a significant percentage of cases and the treatment consisted in the administration of vanco-mycin and normix alone or in combination, along with the treatment of comorbidities. Conclu-sions: Once a relapse occurs the risk of a second relapse is rising, the elderly being most vul-nerable. The use of antibiotics should be limited to situations where they are absolutely needed.

References

1. Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired Clostridium difficile
infection: a population-based study. Am J Gastroenterol. 2012; 107(1):89-95.
2. Cole SA., Stahl TJ. Persistent and Recurrent Clostridium difficile Colitis. Clinics in colon and rectal
surgery, 2015; 28(2): 065-069.
3. Lessa, F. C., et al. Burden of Clostridium difficile infection in the United States. New Engl J Med
2015; 372(9): 825-834.
4. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat
Rev Gastroenterol Hepatol 2011; 8(1): 17-26.
5. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance
of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007; 28(2): 140-145.
6. Cornely, O A. et al. Treatment of First Recurrence of Clostridium Difficile Infection: Fidaxomicin
Versus Vancomycin. Clinical Infectious Diseases 2012; 55(Suppl. 2): S154-S161.
7. Preda, CM, et al. Fecal microbiota transplantation in recurrent NAP1/B1/027 Clostridium difficile
infection (CDI) resistant to Vancomycin and Metronidazole in a patient with ulcerative colitis (UC): a
case report. Rev Med Chir Soc Med Nat Iasi 2016; 120(3): 563-567.

Additional Files

Published

2017-09-30

Issue

Section

INTERNAL MEDICINE - PEDIATRICS